You are here
MASCC/ISOO Mucositis Guidelines: gastrointestinal tract inflammation and ulceration (2013)
MASCC/ISOO Mucositis Guidelines
A comprehensive summary of the Multinational Association of Supportive Care in Cancer (MASCC)/ International Society of Oral Oncology (ISOO) Mucositis Guidelines updated in 2014 is available here. The latest updated version can be found on the MASCC webpage on Mucositis Guidelines, where you can also find links to a selection of free, open access publications on these guidelines.
Mucositis is a serious adverse effect of chemotherapy and radiotherapy treatment for cancer, affecting almost all patients receiving high-dose chemotherapy or hematopoietic stem cell transplantation. It is a painful inflammation and ulceration of the mucous membranes that line the digestive tract. Mucositis can occur anywhere along the gastrointestinal tract. Mucositis in the mouth is a common and in many cases debilitating complication related to cancer treatment, and is referred to as oral mucositis.
The summary referred to above concern the MASCC/ISOO evidence-based clinical practice guidelines for mucositis secondary to cancer therapy. The guidelines make a distinction between Oral mucositis and Gastrointestinal mucositis (other than the oral cavity). For both indications recommendations and suggestions are given in favor of an intervention and against an intervention, based on whether or not there is evidence of effectiveness of the specific treatment option(s) discussed. Specific treatment options include those preventing complications, treating the complications and providing relief of (some aspects of) the comorbidities (e.g. pain relief).